We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.51 | -1.68% | 29.82 | 29.82 | 30.03 | 30.15 | 29.81 | 29.92 | 3,381,439 | 21:00:05 |
From May 2019 to May 2024
By Nathan Allen
Switzerland's Roche Holding AG (ROG.EB) said Monday that a phase-3 trial of its Tecentriq and Avastin treatments showed positive results in patients with a type of advanced kidney cancer.
Roche said the IMmotion 151 trial met its co-primary endpoint, slowing the progression of kidney cancer and helping patients live longer.
The study also showed the combination of Tecentriq and Avastin provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death, compared with patients who received Sunitinib--a conventional treatment--Roche said.
"No new safety signals were identified with the combination," the company added.
Roche said it was continuing to assess secondary endpoints associated with the study and that it would present the results at an oncology conference in 2018.
Write to Nathan Allen at nathan.allen@dowjones.com
(END) Dow Jones Newswires
December 11, 2017 01:44 ET (06:44 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
